Effect of tildrakizumab (MK‐3222), a high affinity, selective anti‐IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis

Por Khalilieh, Sauzanne, Hussain, Azher, Montgomery, Diana, Levine, Vanessa, Shaw, Peter M., Bodrug, Inga, Mekokishvili, Lally, Bailey‐Smith, Candice, Glasgow, Xiaoli S., Cheng, Amy, Martinho, Monika, Iwamoto, Marian
Publicado no Br J Clin Pharmacol (2018)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

Por Krishna, Rajesh, Addy, Carol, Tatosian, Daniel, Glasgow, Xiaoli S., Gendrano III, Isaias Noel, Robberechts, Martine, Haazen, Wouter, de Hoon, J.N., Depré, Marleen, Martucci, Ashley, Peng, Joanna Z., Johnson‐Levonas, Amy O., Wagner, John A., Stoch, S. Aubrey
Publicado no J Clin Pharmacol (2016)